A few enterprising businesses are marketing themselves differently.
This company has massive upside potential, but that's not the whole story.
The $50 million purchase could turn into Nvidia's biggest investment.
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
A lot is riding on whether its platform is valuable, or vaporware.
Morgan Stanley is betting on these stocks to benefit from the AI megatrend.
Recursion is playing the long game with its AI-focused approach to drug discovery and development.
They might not be profitable yet, but they're swinging for the fences.
This stock's upside is huge, but so is its downside.
Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered...